Loading clinical trials...
Loading clinical trials...
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Conditions
Interventions
MSC2363318A
MSC2363318A plus Trastuzumab
+1 more
Locations
15
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
University of California at San Diego, Moores Cancer Center
San Diego, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Metairie Oncology
Metairie, Louisiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
December 13, 2013
Primary Completion Date
August 9, 2018
Completion Date
August 9, 2018
Last Updated
September 19, 2018
NCT05720117
NCT06898450
NCT06658951
NCT05719558
NCT05098132
NCT05101070
Lead Sponsor
EMD Serono
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions